Table 1.
Patient characteristics.
| Number of patients | Total | Upgrading | No upgrading |
|---|---|---|---|
| 322 | 102 | 220 | |
| Age (y), mean ± SD (range) | 66.83 ± 5.9(44–77) | 66.82 ± 6.12(49–77) | 66.85 ± 5.9(44–77) |
| Prostate Weight mean ± SD (range) | 63.7 ± 30.13(12–207) | 65.3 ± 26.2(20–155) | 63.1 ± 31.78(12–207) |
| PSA level (ng/ml), mean ± SD (range) | 11.1 ± 7.39(0.1–47.7) | 12.6 ± 9.98 (2–47.7) | 10.39 ± 5.7(0.1–41) |
| PSA Density (ng/ml2), mean ± SD (range) | 0.261 ± 0.234 (0.001–3.48) | 0.212 ± 0.183(0.035–1.11) | 0.203 ± 0.254(0.00198–3.48) |
| Number of positive cores | 4.8 ± 3.4(1–12) | 4.1 ± 3.07(1–12) | 5.08 ± 3.42(1–12) |
| Maximum percentage of cancer per core | 50.2 ± 30.4(5–100) | 42.5 ± 30.6(5–100) | 53.3 ± 29.52(5–100) |
| PIRADS from mpMRI Benign (1,2) | 17 (5%) | 4 (4%) | 13 (6%) |
| PIRADS 3 | 21 (7%) | 6 (6%) | 15(7%) |
| PIRADS 4 | 78 (24%) | 26 (26%) | 52 (23%) |
| PIRADS 5 | 206 (64%) | 66 (65%) | 140 (64%) |